Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtype.

Department of Histology, University of Medicine and Pharmacy Craiova, Petru Rares Street 2, 200349 Craiova-Dolj, Romania. .
Journal of Histochemistry and Cytochemistry (Impact Factor: 2.4). 03/2009; 57(6):567-75. DOI: 10.1369/jhc.2009.953240
Source: PubMed

ABSTRACT Double or multiple antigen labeling in IHC classically relies on the existence of primary antibodies raised in different species or of different IgG isotypes to ensure the specific labeling with the secondary detection systems. However, suitable pairs of primary antibodies are not always available or the best choice (e.g., as diagnostic tools). During the last few years, several methods have been proposed to overcome this, but none of them offers the flexibility needed for reliable double or multiple enzymatic or fluorescent IHC. We present here a procedure that elutes the antibodies after a first round of immunolabeling, which, in combination with precipitation-based detection systems, allows multiple IHC rounds even for primary antibodies raised in the same species and IgG isotype. Compared with other proposed methods, this procedure ensures a reliable enzymatic or fluorescent staining without cross-reactivity and without loss of tissue antigenicity, thus offering a flexible tool for colocalization studies and pathological diagnosis. This manuscript contains online supplemental material at Please visit this article online to view these materials.

Download full-text


Available from: Daniel Pirici, Sep 08, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biology at a cellular level comes with a great amount of heterogeneity. It is now evident that even clonally propagated cells in an in vitro population do not express the same set of cellular epitopes. The vascular endothelial as well as blood cells show a very high degree of heterogeneity in expression of specific proteins. Although several methods exist for identification of genome or transcriptome from a single cell, there is still limited advancement in detection of multiple cellular antigens in a single cell. This has been mainly due to the limited availability of different antibodies. Single-cell detection methods involving the use of multiple monoclonal antibodies generated in the same species would therefore provide with an important tool for cellular detection of antigens. Here, we describe a method to assess multiple proteins in a cell using different antibodies generated in the same species.
    Journal of immunological methods 03/2012; 379(1-2):42-7. DOI:10.1016/j.jim.2012.02.018 · 2.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: CD25, the alpha subunit of the interleukin-2 (IL-2) receptor, is a canonical marker of regulatory T cells (Tregs) and hence has been implicated in immune suppression in cancer. However, CD25 is also required for optimal expansion and activity of effector T cells in peripheral tissues. Thus, we hypothesized that CD25, in addition to demarcating Tregs, might identify effector T cells in cancer. To investigate this, we used multi-parameter flow cytometry and immunohistochemistry to analyze tumor-infiltrating lymphocytes (TIL) in primary high-grade serous carcinomas (HGSC), the most common and fatal subtype of ovarian cancer. CD25 was expressed primarily by CD4+ TIL, with negligible expression by CD8+ TIL. In addition to conventional CD25+FoxP3+ Tregs, we identified a subset of CD25+FoxP3- T cells that comprised up to 13% of CD4+ TIL. In tumors with CD8+ TIL, CD25+FoxP3- T cells showed a strong positive association with patient survival (HR 0.56, P=0.02), which exceeded the negative effect of Tregs (HR 1.55, P=0.09). Amongst CD4+ TIL subsets, CD25+FoxP3- cells expressed the highest levels of PD-1. Moreover, after in vitro stimulation they failed to produce common T helper cytokines (IFN-γ, TNF-α, IL-2, IL-4, IL-10 or IL-17A), suggesting they were functionally exhausted. In contrast, the more abundant CD25-FoxP3- subset of CD4+ TIL expressed low levels of PD-1 and produced T helper 1 cytokines, yet conferred no prognostic benefit. Thus, CD25 identifies a subset of CD4+FoxP3- TIL that, despite being exhausted at diagnosis, have a strong, positive association with patient survival and warrant consideration as effector T cells for immunotherapy. Copyright © 2014, American Association for Cancer Research.
    12/2014; 3(3). DOI:10.1158/2326-6066.CIR-14-0146
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Krüppel-like factor 5 (KLF5) is a pro-proliferative transcription factor that is expressed in dividing epithelial cells of the intestinal crypt. Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) has been identified as a stem cell marker in both small intestinal and colonic epithelial cells. To determine whether KLF5 regulates proliferation of intestinal stem cells, we investigated the effects of Klf5 deletion specifically from the intestinal stem cells in adult mice. Mice with inducible intestinal stem cell-specific deletion of Klf5 (Lgr5-Klf5fl/fl) were injected with tamoxifen for 5 consecutive days to induce Lgr5-driven Cre expression. Intestinal and colonic tissues were examined by immunohistochemistry at various time points up to 112 days following start of tamoxifen treatment. Klf5 is co-localized in the crypt-based columnar (CBC) cells that express Lgr5. By 11 days following the start of tamoxifen treatment, Lgr5-positive crypts from which Klf5 was deleted exhibited a loss of proliferation that was accompanied by an increase in apoptosis. Beginning at 14 days following the start of tamoxifen treatment, both Klf5 expression and proliferation were re-established in the transit-amplifying epithelial cells but not in the Lgr5-positive CBC cells. By 112 days post-treatment, up to 90% of the Lgr5-positive cells from which Klf5 was deleted were lost from the intestinal crypts. These results indicate a critical role for KLF5 in the survival and maintenance of intestinal stem cells.
    Stem Cell Research 11/2014; 14(1). DOI:10.1016/j.scr.2014.10.008 · 3.91 Impact Factor